Resource centre

Absorption, metabolism and excretion of [14C]-gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.

A Phase I, open-label, 2-Part study to establish absolute bioavailability and the ADME of evogliptin in healthy male subjects by light-label approach.

Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.

Maximising the Potential of Amorphous Spray-Dried Dispersions to Enhance Clinical Bioavailability. Amorphous Dispersions (ADs) provide an effective approach to oral bioavailability improvement for poorly soluble compounds

Absorption of oral peptide-based drug formulations is challenged by the fact that peptides are degraded in the stomach due to low pH and proteolytic enzymes, as well as by their limited permeability across the gastrointestinal epithelium.

When administered orally, peptide-based drugs are susceptible to degradation in the stomach due to exposure to low pH and proteolytic enzymes.

A randomised double-blind dose escalation study to evaluate the safety and dose response of subcutaneous administration of coversin in healthy subjects.

Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers